NASDAQ$KALA
Kala Bio Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Kala Pharmaceuticals reported financial results for the third quarter ended September 30, 2022.
Kala Pharmaceuticals reported a net income of $29.1 million for the third quarter of 2022, which includes a gain on the sale of its commercial business to Alcon of $47.0 million. The company's cash and cash equivalents were $52.4 million as of September 30, 2022, expected to fund operations into Q2 2024. Kala plans to initiate a Phase 2/3 clinical trial of KPI-012 in PCED patients in the fourth quarter of 2022.
- Kala plans to initiate a Phase 2/3 clinical trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022, with topline data expected in 1Q 2024.
- The company ended the quarter with $52.4 million in cash, which is sufficient for funding operations into 2Q 2024.
- Net product revenues for the quarter ended September 30, 2022, were $0.4 million, representing approximately one week of net product revenues from sales of EYSUVIS and INVELTYS.
- Kala anticipates approximately a 50% reduction in non-GAAP operating expenses in the second half of 2022 as compared to the first half of 2022.
Headline financials
Revenue & EPS history
Kala Bio · Revenue · Quarterly
$420K
Forward guidance
Kala anticipates approximately a 50% reduction in non-GAAP operating expenses in the second half of 2022 as compared to the first half of 2022 and a 60-70% reduction in non-GAAP total operating expenses for the full year 2023 compared to the full year 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2022
+1.5%
Avg return
Earnings day
+0.1%
Avg return
5 days after
-4.7%
Avg return
30 days after
40%
14 / 35 earnings
Positive
+119.7%
Q4 2022
Best reaction
-18.3%
Q1 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.6% | -17.4% | -17.7% | |
| Q3 2025 | -7.4% | -10.4% | -9.7% | |
| Q2 2025 | +2.0% | +9.9% | +103.2% | |
| Q1 2025 | -5.0% | +4.6% | +23.6% | |
| Q4 2024 | -1.5% | +1.5% | +0.0% | |
| Q3 2024 | -6.1% | -9.5% | -17.7% | |
| Q2 2024 | +3.2% | -1.7% | -1.7% | |
| Q1 2024 | -0.9% | -3.9% | -12.0% | |
| Q4 2023 | +0.3% | -2.4% | -21.0% | |
| Q3 2023 | -6.6% | -2.2% | +19.7% | |
| Q2 2023 | -6.5% | -8.4% | -7.9% | |
| Q1 2023 | -2.8% | +3.0% | -5.3% | |
| Q4 2022 | +119.7% | +114.5% | +48.0% | |
| Q3 2022 | +23.7% | +34.9% | -1.9% | |
| Q2 2022 | -3.4% | -4.6% | -1.7% | |
| Q1 2022 | +8.2% | -5.4% | -43.1% | |
| Q4 2021 | -16.6% | -25.1% | -61.9% | |
| Q3 2021 | +4.3% | -7.7% | -30.4% | |
| Q2 2021 | -6.3% | -4.8% | -2.7% | |
| Q1 2021 | -18.3% | -18.4% | -9.0% | |
| Q4 2020 | -17.0% | -17.6% | -21.4% | |
| Q3 2020 | -1.8% | +0.6% | +2.5% | |
| Q2 2020 | -2.7% | -2.5% | -13.2% | |
| Q1 2020 | -2.8% | +2.8% | +17.0% | |
| Q4 2019 | +3.5% | +1.6% | +1.3% | |
| Q3 2019 | +7.0% | -4.4% | +4.2% | |
| Q2 2019 | +1.2% | -0.6% | -20.6% | |
| Q1 2019 | -8.6% | -17.2% | -24.2% | |
| Q4 2018 | +1.0% | +6.6% | -1.6% | |
| Q3 2018 | -5.4% | -13.8% | -25.9% | |
| Q2 2018 | +1.6% | -3.9% | -8.5% | |
| Q1 2018 | +2.0% | +3.7% | -16.0% | |
| Q4 2017 | -7.1% | -7.4% | -7.4% | |
| Q3 2017 | -3.6% | +2.6% | +1.7% | |
| Q2 2017 | +5.4% | +6.2% | -3.7% | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro